Literature DB >> 8507813

Angiotensin-converting enzyme inhibitor fetopathy.

P G Pryde1, A B Sedman, C E Nugent, M Barr.   

Abstract

Angiotensin-converting enzyme (ACE) inhibitors are widely used for controlling hypertension. Their use in women who are pregnant is not without risk to the fetus. We describe three infants exposed in utero to ACE inhibitors who had adverse outcomes. These cases, combined with other reports in the literature, suggest strongly that these drugs are fetotoxic. ACE inhibitor fetopathy is characterized by fetal hypotension, anuria-oligohydramnios, growth restriction, pulmonary hypoplasia, renal tubular dysplasia, and hypocalvaria. Although the true frequency of adverse fetal effects has yet to be determined, because of the debilitating and lethal nature of the fetal damage when it occurs, it is our recommendation that ACE inhibitors not be used in pregnancy, particularly in the second and third trimesters.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507813     DOI: 10.1681/ASN.V391575

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  56 in total

1.  Twin-to-twin transfusion syndrome. Role of the fetal renin-angiotensin system.

Authors:  D Mahieu-Caputo; M Dommergues; A L Delezoide; M Lacoste; Y Cai; F Narcy; D Jolly; M Gonzales; Y Dumez; M C Gubler
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

Review 2.  Drug-induced congenital defects: strategies to reduce the incidence.

Authors:  M De Santis; B Carducci; A F Cavaliere; L De Santis; G Straface; A Caruso
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Taking ACE inhibitors during pregnancy. Is it safe?

Authors:  Savithiri Ratnapalan; Gideon Koren
Journal:  Can Fam Physician       Date:  2002-06       Impact factor: 3.275

4.  Abnormal skull findings in neural tube defects.

Authors:  Laura Imbruglia; Alessandra Cacciatore; Sabina Carrara; Stefania Recupero; Tindara La Galia; Elisa Maria Pappalardo; Manuela Chiara Accardi; Rosa Pedata; Giusi Rapisarda; Alessia Mammaro
Journal:  J Prenat Med       Date:  2009-07

5.  Dependence of renal microvessel density on angiotensin II: only in the fetus?

Authors:  Barbara J Ballermann
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121

6.  Renal tubular dysgenesis associated with in utero exposure to Nimuselide.

Authors:  Uma Sankari Ali; Sheila Khubchandani; Parmanand Andankar; Shashank Parekhji; Vishal Dubhalish; Bhavna Padhye
Journal:  Pediatr Nephrol       Date:  2005-12-03       Impact factor: 3.714

7.  Angiotensin induces the urinary peristaltic machinery during the perinatal period.

Authors:  Y Miyazaki; S Tsuchida; H Nishimura; J C Pope; R C Harris; J M McKanna; T Inagami; B L Hogan; A Fogo; I Ichikawa
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

Review 8.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

Review 9.  Stage 1 chronic kidney disease in pregnancy.

Authors:  Tiina Podymow; Phyllis August
Journal:  Obstet Med       Date:  2012-09-17

10.  Congenital unilateral renal tubular dysgenesis and severe neonatal hypertension.

Authors:  Danielle Delaney; Sean E Kennedy; Vivienne H Tobias; Robert H Farnsworth
Journal:  Pediatr Nephrol       Date:  2008-11-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.